First joint project launches a broader platform strategy for process orchestration across the clinical trial lifecycle  

Oversubscribed €120 million Series D financing was led by M Ventures and Revelation Partners, with new investors Angelini Industries, the European Investment Bank and Neva SGR and participation from all existing investors. Proceeds will fund advancement of Nouscom’s lead asset NOUS-209, an investigational, off-the-shelf neoantigen-based cancer immunotherapy, through a global, registration-enab

Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours) Deucrictibant IR showed a well-tolerated safety profile NDA and MAA of deucrictibant IR for the on-demand treatment of HAE attacks under review by regulatory authorities

First publication reveals how roginolisib uniquely locks the cancer-driving enzyme PI3Kδ in an inactive state, differentiating the drug from other PI3Kδ inhibitors Second publication outlines first-in-human (FiH) study results, demonstrating roginolisib’s favorable tolerability profile and encouraging clinical findings in patients with cancer Publication comes as iOnctura awaits readouts from